Trial Profile
An Open-label Clinical Trial Phase IIB to Evaluate the Immunogenicity and Safety of Recombinant Novel Coronavirus Vaccine in Participants Aged 18 Years and Above That Previously Received One Dose of Sputnik V
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 16 Mar 2023
Price :
$35
*
At a glance
- Drugs Ad5-nCoV Tianjin CanSino Biotechnology (Primary)
- Indications COVID 2019 infections
- Focus Pharmacodynamics
- 11 Mar 2023 Planned End Date changed from 15 Jan 2023 to 15 Apr 2023.
- 28 Sep 2022 Planned End Date changed from 15 Jul 2022 to 15 Jan 2023.
- 28 Sep 2022 Planned primary completion date changed from 15 Jun 2022 to 15 Nov 2022.